Prognostic value of the C-reactive protein/albumin ratio in patients with laryngeal squamous cell carcinoma

Figures & data

Figure 1 ROC curve analysis of the CRP/ALB ratio for survival status among the 129 patients with LSCC.

Notes: The optimal cutoff value was 0.047 according to the ROC analysis (area 0.62 [95% CI, 0.52–0.72], P<0.05). Diagonal segments are produced by ties. Green line represents reference line. Blue line represents the curve for CRP/ALB ratio.
Abbreviations: CI, confidence interval; CRP/ALB, C-reactive protein/albumin; LSCC, laryngeal squamous cell carcinoma; ROC, receiver operating characteristic.

Table 1 Patient demographics and clinical characteristics

Characteristics	Total n, (%)	CRP/ALB ratio		P-value
		<0.047 n, (%)	≥0.047 n, (%)
Total	129	73	56
Age, years				0.53
≤60	64 (49.6)	38 (52.1)	26 (46.4)
>60	65 (50.4)	35 (47.9)	30 (53.6)
Sex				0.30
Male	119 (92.2)	66 (90.4)	53 (94.6)
Female	10 (7.8)	7 (9.6)	3 (5.4)
Smoking status				0.96
Nonsmokers or ex-smokers	51 (39.6)	29 (39.7)	22 (39.2)
Smokers	78 (60.4)	44 (60.3)	34 (60.8)
Nodal classification				<0.01
N0	87 (67.4)	57 (78.1)	30 (53.6)
N+	42 (32.6)	16 (21.9)	26 (46.4)
Disease stage				<0.05
I/II	80 (62.0)	51 (69.9)	29 (51.8)
III/IV	49 (38.0)	22 (30.1)	27 (48.2)
Recurrence				<0.05
Yes	46 (35.6)	20 (27.4)	27 (48.2)
No	83 (64.4)	53 (72.6)	29 (51.8)

Abbreviation: CRP/ALB, C-reactive protein/albumin.

Figure 2 Overall survival curves for the 129 patients with LSCC stratified by the CRP/ALB ratio (P<0.01).

Abbreviations: CRP/ALB, C-reactive protein/albumin; LSCC, laryngeal squamous cell carcinoma.

Table 2 Univariate Cox regression analysis for OS and DFS in patients with laryngeal squamous cell carcinoma

Variables	No of patients	OS			DFS
		No of events	HR (95% CI)	P-value	No of events	HR (95% CI)	P-value
Sex				0.11			0.08
Male	119	39			43
Female	10	1	0.20 (0.03–1.47)		1	0.18 (0.02–1.28)
Age, years				0.26			0.97
≤60	64	23			22
>60	65	17	0.70 (0.37–1.31)		22	0.97 (0.54–1.75)
Smoking				0.78			0.67
Nonsmoker or ex-smoker	51	19			20
Smoker	78	21	1.23 (0.67–1.99)		24	1.06 (0.56–1.76)
Nodal classification				<0.01			<0.01
N0	87	14			22
N+	42	26	4.58 (2.42–8.61)		20	2.43 (1.33–4.45)
Disease stage				,0.01			<0.01
I/II	80	12			19	4.68 (2.49–8.81)
III/IV	49	28	5.94 (2.99–11.78)		25
CRP/ALB ratio				<0.05			<0.01
<0.047	73	17			18
≥0.047	56	23	2.13 (1.15–3.93)		26	2.36 (1.28–4.36)

Abbreviations: CRP/ALB, C-reactive protein/albumin; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

Table 3 Multivariate Cox regression analysis for OS and DFS in patients with laryngeal squamous cell carcinoma

Variables	No of patients	OS		DFS
		HR (95% CI)	P-value	HR (95% CI)	P-value
Nodal classification			<0.05		0.72
N0	87
N+	42	2.56 (1.12–5.87)		1.15 (0.545–2.41)
Disease stage			<0.01		<0.01
I/II	80
III/IV	49	3.20 (1.36–7.48)		2.91 (1.40–6.07)
CRP/ALB ratio			<0.05		<0.05
<0.047	73	2.56 (1.09–5.86)		1.97 (1.12–4.06)
≥0.047	56

Abbreviations: CRP/ALB, C-reactive protein/albumin; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.